Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim

Di cosa scriviamo

FarmaceuticaImpreseIndustriaMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

12 comunicati stampa

Guarda tutti i comunicati
04/11/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
30/10/2026
Farmaceutica
Medicina Salute Benessere
Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
22/10/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
29/09/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
23/09/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
16/09/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
11/08/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
15/07/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
03/09/2025
Boehringer Ingelheim Launches Swine Vaccine With Advanced Protection Against Porcine Circovirus Type 2 in the United States
Fonte
Boehringer Ingelheim
Emittente
Business Wire
1.00
0
Press Release cover image
22/11/2024
Farmaceutica
Sanità
Economia
Start-up
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Fonte
Boehringer Ingelheim
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0